The Food and Drug Administration announced on Apr. 14 that it has contacted more than 2,200 study sponsors to remind them of their legal obligation to make clinical trial results publicly available on the federal database clinicaltrials.gov.
This action is part of the FDA's broader effort to improve transparency in drug development and ensure that both positive and negative outcomes are accessible to patients, researchers, and the public. The agency found that nearly 30% of studies required by law to report results had not met this requirement.
According to an internal review by the FDA, failure to fully report findings—often those with negative outcomes—creates “significant gaps in the public record” and “obscures the true landscape of drug development outcomes—overrepresenting successes and underrepresenting failures.” The agency is seeking voluntary compliance from sponsors but warned that continued noncompliance could result in civil penalties or even criminal prosecution.
The letters sent out on March 30 provide an additional opportunity for responsible parties to meet their obligations before further regulatory action is considered. Commissioner Marty Makary said Monday in a prepared statement: “Far too often, companies are suppressing unfavorable clinical trial results and keeping them secret from patients and the scientific community.” Makary added that trial sponsors have an “ethical obligation” to disclose their results publicly, regardless of how they might affect company share prices.
The FDA’s push for greater openness follows its July 2025 initiative when it began publishing more than 200 complete response letters explaining its reasons for rejecting certain drugs. While some information remains redacted for intellectual property reasons, analysts say these disclosures have improved accountability within the pharmaceutical industry. TD Cowen senior biotechnology analyst Ritu Baral told BioSpace earlier this month: “The reception from the investment community has been unanimously positive.”
Observers expect these transparency measures will continue shaping industry practices as regulators seek a clearer view into all aspects of drug development.
